New York, February 4, 2026, 14:47 EST — Regular session
- Shares of Procter & Gamble climbed roughly 1.8% in afternoon trading, building on their recent winning streak
- A company officer has filed paperwork to possibly sell roughly $11 million worth of stock under Rule 144
- As tech stocks slide and crucial earnings and data come in, investors are closely watching to see if the defensive bid remains intact
Procter & Gamble shares climbed roughly 1.8% on Wednesday, hitting $158.37 at their peak before settling around $158.16 in early afternoon trading in New York. The stock was last seen near the session’s upper end.
The shift is significant as the tape grows jittery once more. Big tech and software stocks are under pressure amid renewed concerns over how quickly artificial intelligence is altering pricing power and profit margins. Meanwhile, some funds are rotating into “consumer staples” — producers of everyday essentials that typically hold steady when risk appetite wanes.
The shift has been abrupt this week, despite the wider market feeling sluggish. “We’re seeing a lot of software companies across the spectrum get hit,” Art Hogan, chief market strategist at B. Riley Wealth, noted in a report on the tech-driven selloff. (Reuters)
P&G ended Tuesday at $155.32, gaining 1.39% while the S&P 500 slipped. Despite the uptick, the stock still trades far below its 52-week peak, according to MarketWatch data. (MarketWatch)
Investors should note that Gary A. Coombe, an officer, filed a Form 144 to sell up to 72,186 shares worth roughly $11.0 million, targeting a sale date around Feb. 4. This filing signals an insider’s intent to sell but doesn’t confirm the shares have been sold yet. (SEC)
Company fundamentals remain intact. On Jan. 22, P&G reported quarterly results, slightly missing revenue estimates but beating profit forecasts and sticking to its annual guidance. CFO Andre Schulten told analysts, “We need to get the U.S. growing.” At the time, David Wagner, head of equities at Aptus Capital Advisors, noted the market might “look past” the organic sales miss. (Organic sales exclude currency fluctuations and acquisition impacts.) (Reuters)
This week, the stock’s bid pushed it to trade more like a macro proxy than a pure single-name play — a spot investors flock to when growth feels overpriced. Traders are now eyeing whether staples can sustain inflows if tech steadies heading into the close.
There is a downside risk, though. If U.S. consumers continue trading down and sales volumes remain weak, P&G’s grip on pricing could slip, letting margin pressures from rising costs resurface quickly. A pullback in the “defensive” trade or an unexpected surge in insider selling might also deflate the rally.
The upcoming focus for the sector is the CAGNY conference, with P&G set to present on Feb. 19. Kimberly-Clark and Colgate-Palmolive are also slated to speak at the event.
Broader risk appetite in the short term may depend heavily on big tech earnings and the delayed U.S. labor data following the government shutdown disruption. “The market is suddenly skeptical and concerned about it,” said Jed Ellerbroek, a portfolio manager at Argent Capital, commenting on the AI-driven repricing in tech. For P&G investors, the next key date is the Feb. 19 conference slot. (Reuters)
